Surrozen, Inc./DE Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value
Surrozen, Inc./DE (SRZN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value of $19.43 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue · last filed 2026-08-06
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2026-03-31 was $19.24, a 100.21% increase year-over-year.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2025-03-31 was $9.61, a 60.17% increase year-over-year.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2024-03-31 was $6.00, a 39.39% decline year-over-year.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for the quarter ending 2023-03-31 was $9.90, a 314.23% increase year-over-year.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2025 was $9.09, a 22.01% increase from fiscal 2024.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2024 was $7.45, a 21.33% decline from fiscal 2023.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2023 was $9.47, a 72.31% decline from fiscal 2022.
- Surrozen, Inc./DE share-based compensation arrangement by share-based payment award, options, vested, weighted average grant date fair value for fiscal 2022 was $34.20, a 437.74% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $19.43 10-Q · filed 2026-08-06 | |||||||
| 2026-03-31 | $19.24 10-Q · filed 2026-05-06 | |||||||
| 2025-12-31 | $9.09 10-K · filed 2026-03-23 | |||||||
| 2025-09-30 | $9.01 10-Q · filed 2025-11-07 | |||||||
| 2025-06-30 | $8.97 10-Q · filed 2026-08-06 | |||||||
| 2025-03-31 | $9.61 10-Q · filed 2026-05-06 | |||||||
| 2024-12-31 | $7.45 10-K · filed 2026-03-23 | |||||||
| 2024-09-30 | $7.45 10-Q · filed 2025-11-07 | |||||||
| 2024-06-30 | $7.45 10-Q · filed 2025-08-08 | |||||||
| 2024-03-31 | $6.00 10-Q · filed 2025-05-09 | |||||||
| 2023-12-31 | $9.47 10-K · filed 2025-03-31 | |||||||
| 2023-09-30 | $9.47 10-Q · filed 2024-11-06 | $0.63 10-Q · filed 2023-11-08 | ||||||
| 2023-06-30 | $9.47 10-Q · filed 2024-08-12 | $0.63 10-Q · filed 2023-08-09 | ||||||
| 2023-03-31 | $9.90 10-Q · filed 2024-05-08 | $0.66 10-Q · filed 2023-05-10 | ||||||
| 2022-12-31 | $34.20 10-K · filed 2024-04-10 | $2.28 10-K · filed 2023-03-31 | ||||||
| 2022-09-30 | $2.31 10-Q · filed 2023-11-08 | |||||||
| 2022-06-30 | $2.34 10-Q · filed 2023-08-09 | |||||||
| 2022-03-31 | $2.39 10-Q · filed 2023-05-10 | |||||||
| 2021-12-31 | $6.36 10-K · filed 2023-03-31 | |||||||
| 2021-09-30 | $6.51 10-Q · filed 2021-11-15 | |||||||
| 2020-12-31 | $0.74 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |